EUCTR2010-021082-74-IT进行中（未招募）不适用
Randomized, placebo-controlled, double-blind Phase 1b/2 study of U3-1287 (AMG 888) in combination with erlotinib in EGFR treatment naïve subjects with advanced non-small cell lung cancer (NSCLC) who have progressed on at least one prior chemotherapy.
DAIICHI SANKYO PHARMA DEVELOPMENT0 个研究点目标入组 210 人开始时间: 2011年12月29日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must satisfy all of the following criteria to be included in the study: 1. Men or women ³ 18 years old. 2. Histologically or cytologically confirmed NSCLC with either: - Metastatic disease (Stage IV) OR - Stage IIIB disease not amenable to surgery or curative intent. 3. Disease progression or recurrence following treatment after last chemotherapy or chemoradiation regimen (completed within the previous 12 months)documented by radiographic assessment. 4. Measurable disease per RECIST guidelines Version 1.1. 5. Eastern Cooperative Oncology Group (ECOG)performance status 0 or 1. 6. Hematological function, as follows: - Absolute neutrophil count (ANC)³ 1.5´ 109/L - Platelet count ³ 100 ´ 109/L - Hemoglobin ³ 9 g/dL. 7. Renal function, as follows: - Calculated creatinine clearance³ 60 mL/min using the modified Cockroft-Gault equation or serum creatinine Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Left ventricular ejection fraction (LVEF) < 45%. 2. Prior EGFR-targeted regimen, anti-HER2, anti-HER3, or anti-HER4 therapy. 3. More than 2 prior chemotherapy regimens for this indication (Phase 2 subjects only). 4. History of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease for³ 5 years. 5. History of corneal disease. 6. History of interstitial lung disease. 7. Clinically active brain metastases, defined as untreated symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Subjects with treated brain metastases that are no longer symptomatic and require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 4 weeks (2 weeks for subjects with a solitary brain lesion amenable to sterotactic radiosurgery) must have elapsed between the end of radiotherapy and study enrollment. 8. Uncontrolled hypertension (diastolic > 100 mmHg or systolic > 140 mmHg). It is permissible for the subject to receive treatment with antihypertensive medication to maintain blood pressure within required parameters. 9. Clinically significant electrocardiogram (ECG) changes that obscure the ability to assess the RR, PR, QT, QTc, and QRS intervals. 10. Ascites or pleural effusion requiring chronic medical intervention. 11. Myocardial infarction within 1 year before enrollment, symptomatic congestive heart failure (New York Heart Association >Class II), unstable angina, or unstable cardiac arrhythmia requiring medication. 12. Treatment with anticancer therapy, antibody-based therapy, retinoid therapy, or hormonal therapy within 4 weeks before study drug treatment or treatment with nitrosoureas or mitomycin C within 6 weeks before study drug treatment or treatment with small molecule tyrosine kinase inhibitors(TKIs) within 2 weeks before study drug treatment. Prior and concurrent use of hormone replacement therapy is permitted. 13. Therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment or palliative radiation therapy within 2 weeks before study drug treatment. Radiation treatment to all sites of measureable disease unless progression is documented after radiation. No target lesion should be selected within the previously irradiated field unless there was progression at that lesion following radiation. 14. Participated in clinical drug trials within 4 weeks (2 weeks for small molecule TKIs) before study drug treatment. Current participation in other investigational procedures. 15. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection. 16. History of hypersensitivity to any of the study drugs or to any excipients. 17. Concurrent use of CYP3A4 inducers or inhibitors. 18. Any known pre-existing condition including substance abuse that could interfere with subjectâ??s participation in and completion of the protocol.
研究者
相似试验
进行中（未招募）
2 期
Randomized, double-blind, placebo controlled Phase II study to evaluate the efficacy and safety of Sorafenib treatment in patients with advanced (recurrent, persistent and/or metastasizing) medullary thyroid carcinoma (SUMMIT).C73Malignant neoplasm of thyroid glandDRKS00004455EANM Forschungs GmbH/ EANM Research Ltd.
尚未招募
2 期
Randomised, double-blind, placebo controlled phase II study of the efficacy of Phospha-E biomarkers of inflammation, in patients with metabolic syndrome and mild to moderate hyperlipidemia.Metabolic SyndromeMetabolic and Endocrine - Other metabolic and endocrine disordersACTRN12607000343404Phosphagenics Limited160
已完成
3 期
Melatonin vs. placebo for prevention of delirium in hospital in people with advanced cancerDeliriumACTRN12616001618448niversity Technology Sydney221
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled Phase II proof-of-concept study of APD515 solution for oromucosal and oral administration for relief of xerostomia in patients with cancer - Phase II PoC study of APD515 v1.2XerostomiaMedDRA version: 14.0Level: LLTClassification code 10048223Term: XerostomiaSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-000978-53-DKAcacia Pharma Ltd30
已完成
1 期
A Phase I study of orally inhaled PB01 in healthy male participants following single and repeat administration.ACTRN12615000984594Paranta Biosciences Ltd56